Registrant’s telephone number, including area code: ~~(858) 207-4264~~(617) 715-3600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 3, 2020,~~July 23, 2021, there were ~~27,381,195~~27,488,137 shares of common stock outstanding.

	September 30,			December 31,			June 30,			December 31,
	2020			2019			2021			2020
	(Unaudited)						(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	27,760		$	87,820		$	45,888		$	21,221
Accounts receivable, net		3,929			2,960			8,596			5,834
Inventory, net		7,274			2,211			5,481			6,013
Prepaid expenses and other current assets		3,240			4,467			5,201			3,388
Total current assets		42,203			97,458			65,166			36,456
Goodwill								20,123			20,123
Intangible assets, net								14,097			14,873
Right-of-use lease assets								419			536
Property and equipment, net		284			18,389			163			215
Right-of-use lease assets		2,150			15,491
Restricted cash		699			909			40			40
Intangible assets, net		15,261			-
Goodwill		20,123			-
Total assets	$	80,720		$	132,247		$	100,008		$	72,243

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	3,928		$	4,177		$	1,846		$	2,762
Accrued expenses		7,683			9,312			12,175			6,494
Accrued payroll and related expenses		6,164			8,332			1,912			2,878
Lease liabilities, current portion		985			2,766			168			204
Total current liabilities		18,760			24,587			16,101			12,338
Deferred royalty obligation, net								124,470			124,437
Accrued interest expense on deferred royalty obligation, less current portion								22,136			19,111
Lease liabilities, less current portion		1,249			26,481			251			332
Deferred royalty obligation, net		124,421			124,379
Other noncurrent liabilities		21,805			12,790			4,493			4,112
Total liabilities	$	166,235		$	188,237			167,451			160,330
Commitments and contingencies (Note 6)
Shareholders’ deficit:
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,378,048 and 27,195,469 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		3			3
Series C-1² Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at September 30, 2020 and December 31, 2019; and liquidation preference of $3,906 at September 30, 2020 and December 31, 2019		3,906			3,906
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,482,231 and 27,402,648 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively								3			3
Series C-1² Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at June 30, 2021 and December 31, 2020								3,906			3,906
Additional paid-in capital		983,850			977,432			987,249			984,756
Accumulated deficit		(1,073,274	)		(1,037,331	)		(1,058,601	)		(1,076,752	)
Total shareholders’ deficit		(85,515	)		(55,990	)		(67,443	)		(88,087	)
Total liabilities and shareholders’ deficit	$	80,720		$	132,247		$	100,008		$	72,243

	Three Months Ended						Nine Months Ended						Three Months Ended						Six Months Ended
	September 30,						September 30,						June 30,						June 30,
	2020			2019			2020			2019			2021			2020			2021			2020
Revenue
Net product sales	$	9,072		$	5,706		$	22,468		$	15,804		$	11,059		$	5,805		$	19,696		$	13,396
License revenue														5,000			-			30,500			-
Total revenue		9,072			5,706			22,468			15,804			16,059			5,805			50,196			13,396
Operating expenses
Cost of product sales		2,489			554			4,013			1,605			2,156			808			4,887			1,524
Cost of license revenue														-			-			3,600			-
Selling, general and administrative														8,996			8,677			17,751			16,829
Research and development		3,617			21,182			21,581			64,469			1,114			8,781			2,672			17,964
Selling, general and administrative		12,493			10,782			29,322			34,425
Total operating expenses		18,599			32,518			54,916			100,499			12,266			18,266			28,910			36,317
Loss from operations		(9,527	)		(26,812	)		(32,448	)		(84,695	)
Other income (expense)
Income (loss) from operations														3,793			(12,461	)		21,286			(22,921	)
Other (expense) income
Interest expense		(2,526	)		(2,863	)		(7,402	)		(8,398	)		(2,672	)		(2,470	)		(5,281	)		(4,876	)
Interest income		12			501			234			1,818			-			32			2			222
Other income—related party		-			-			4,085			-			2,532			-			2,532			4,085
Other income (expense)		281			-			(412	)		-			80			(693	)		(370	)		(693	)
Total other income (expense), net		(2,233	)		(2,362	)		(3,495	)		(6,580	)
Net loss	$	(11,760	)	$	(29,174	)	$	(35,943	)	$	(91,275	)
Net loss per share, basic and diluted	$	(0.43	)	$	(1.08	)	$	(1.32	)	$	(3.37	)
Weighted-average common shares outstanding, basic and diluted		27,368			27,135			27,311			27,093
Total other (expense) income, net														(60	)		(3,131	)		(3,117	)		(1,262	)
Income (loss) before income taxes														3,733			(15,592	)		18,169			(24,183	)
Provision for income taxes														-			-			18			-
Net income (loss)													$	3,733		$	(15,592	)	$	18,151		$	(24,183	)
Earnings (loss) per share
Basic													$	0.14		$	(0.57	)	$	0.66		$	(0.89	)
Diluted													$	0.11		$	(0.57	)	$	0.53		$	(0.89	)
Shares used in computing earnings (loss) per share
Basic														27,461			27,326			27,444			27,282
Diluted														34,201			27,326			34,192			27,282

Condensed Consolidated Statements of Shareholders’ ~~(Deficit) Equity~~Deficit

	Series C-1² Convertible Preferred Stock				Series F Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Shareholders' (Deficit)			Series C-1² Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Shareholders’ (Deficit)
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Equity			Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at December 31, 2019		4	$	3,906		-	$	-		27,195	$	3	$	977,432	$	(1,037,331	)	$	(55,990	)
Balance at December 31, 2020																						4	$	3,906		27,403	$	3	$	984,756	$	(1,076,752	)	$	(88,087	)
Share-based compensation expense		-		-		-		-		-		-		2,407		-			2,407			-		-		-		-		1,116		-			1,116
Issuance of common stock under 2013 Equity Plan		-		-		-		-		44		-		305		-			305			-		-		29		-		154		-			154
Issuance of common stock under ESPP		-		-		-		-		38		-		200		-			200			-		-		17		-		81		-			81
Net loss		-		-		-		-		-		-		-		(8,591	)		(8,591	)
Balance at March 31, 2020		4		3,906		-		-		27,277		3		980,344		(1,045,922	)		(61,669	)
Net income																						-		-		-		-		-		14,418			14,418
Balance at March 31, 2021																						4	$	3,906		27,449	$	3	$	986,107	$	(1,062,334	)	$	(72,318	)
Share-based compensation expense		-		-		-		-		-		-		1,590		-			1,590			-		-		-		-		1,024		-			1,024
Issuance of common stock under 2013 Equity Plan		-		-		-		-		50		-		300		-			300			-		-		-		-		1		-			1
Issuance of common stock under ESPP		-		-		-		-		32		-		159		-			159			-		-		33		-		117		-			117
Net loss		-		-		-		-		-		-		-		(15,592	)		(15,592	)
Balance at June 30, 2020		4		3,906		-		-		27,359		3		982,393		(1,061,514	)		(75,212	)
Share-based compensation expense		-		-		-		-		-		-		1,388		-			1,388
Issuance of common stock under ESPP		-		-		-		-		19		-		69		-			69
Net loss		-		-		-		-		-		-		-		(11,760	)		(11,760	)
Balance at September 30, 2020		4	$	3,906		-	$	-		27,378	$	3	$	983,850	$	(1,073,274	)	$	(85,515	)
Net income																						-		-		-		-				3,733			3,733
Balance at June 30, 2021																						4	$	3,906		27,482	$	3	$	987,249	$	(1,058,601	)	$	(67,443	)

	Series C-1² Convertible Preferred Stock				Series F Convertible Preferred Stock						Common Stock				Additional Paid-in			Accumulated			Total Shareholders' (Deficit)			Series C-1² Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Shareholders’ (Deficit)
	Shares		Amount		Shares			Amount			Shares		Amount		Capital			Deficit			Equity			Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at December 31, 2018		4	$	3,906		3		$	2,737			26,259	$	3	$	950,258		$	(920,983	)	$	35,921
Balance at December 31, 2019																									4	$	3,906		27,195	$	3	$	977,432	$	(1,037,331	)	$	(55,990	)
Share-based compensation expense		-		-		-			-			-		-		6,782			-			6,782			-		-		-		-		2,407		-			2,407
Issuance of common stock under ESPP		-		-		-			-			52		-		283			-			283
Issuance of common stock for conversion of Series F Preferred Stock		-		-		(3	)		(2,737	)		782		-		2,737			-			-
Cumulative-effect adjustment from adoption of ASU 2018-07		-		-		-			-			-		-		(160	)		160			-
Net loss		-		-		-			-			-		-		-			(31,685	)		(31,685	)
Balance at March 31, 2019		4		3,906		-			-			27,093		3		959,900			(952,508	)		11,301
Share-based compensation expense		-		-		-			-			-		-		6,321			-			6,321
Issuance of common stock under 2013 Equity Plan																									-		-		44		-		305		-			305
Issuance of common stock under ESPP		-		-		-			-			32		-		201			-			201			-		-		38		-		200		-			200
Net loss		-		-		-			-			-		-		-			(30,416	)		(30,416	)		-		-		-		-		-		(8,591	)		(8,591	)
Balance at June 30, 2019		4		3,906		-			-			27,125		3		966,422			(982,924	)		(12,593	)
Balance at March 31, 2020																									4	$	3,906		27,277	$	3	$	980,344	$	(1,045,922	)	$	(61,669	)
Share-based compensation expense		-		-		-			-			-		-		6,419			-			6,419			-		-		-		-		1,590		-			1,590
Issuance of common stock under 2013 Equity Plan																									-		-		50		-		300		-			300
Issuance of common stock under ESPP		-		-		-			-			22		-		177			-			177			-		-		32		-		159		-			159
Net loss		-		-		-			-			-		-		-			(29,174	)		(29,174	)		-		-		-		-		-		(15,592	)		(15,592	)
Balance at September 30, 2019		4	$	3,906		-		$	-			27,147	$	3	$	973,018		$	(1,012,098	)	$	(35,171	)
Balance at June 30, 2020																									4	$	3,906		27,359	$	3	$	982,393	$	(1,061,514	)	$	(75,212	)

	Nine Months Ended						Six Months Ended
	September 30,						June 30,
	2020			2019			2021			2020
Operating activities
Net loss	$	(35,943	)	$	(91,275	)
Adjustments to reconcile net loss to net cash used for operating activities:
Net income (loss)							$	18,151		$	(24,183	)
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Share-based compensation expense		5,385			19,522			2,140			3,997
Depreciation expense		2,155			3,408			56			1,798
Non-cash interest expense								3,718			3,392
Inventory fair value step-up adjustment included in cost of product sales		1,186			-			850			-
Amortization of intangible assets		259			-			776			-
Loss on change in fair value of contingent value rights								370			-
Amortization of right-of-use lease assets		1,091			969			117			699
Non-cash interest expense		5,339			6,971
Loss on short-term investments		502			-
Loss on disposal of property and equipment, net of gain on lease termination		59			15
Loss on disposal of property and equipment								-			904
Unrealized gains on short-term investments								-			(63	)
Changes in operating assets and liabilities:
Accounts receivable, net		218			(36	)		(2,762	)		1,117
Inventory, net		(1,482	)		110			(318	)		(909	)
Prepaid expenses and other current assets		2,445			328			(1,813	)		1,675
Accounts payable		(1,649	)		(3,234	)		(920	)		(1,696	)
Accrued expenses		(5,786	)		(332	)		5,032			(3,378	)
Accrued payroll and related expenses		(2,168	)		(2,391	)		(966	)		(2,591	)
Lease liabilities		(1,969	)		(1,873	)		(117	)		(1,357	)
Net cash used for operating activities		(30,358	)		(67,818	)
Net cash provided by (used for) operating activities								24,314			(20,595	)
Investing activities
Acquisition of Tetraphase, net of cash, cash equivalents and restricted cash acquired		(33,513	)		-
Proceeds from the sale of property and equipment		3,070			-			-			2,860
Purchases of property and equipment		-			(679	)
Proceeds from the sale of short-term investments		2,497			-
Purchases of short-term investments		(2,999	)		-			-			(2,999	)
Net cash used for investing activities		(30,945	)		(679	)		-			(139	)
Financing activities
Net proceeds from issuance of common stock under 2013 Equity Plan		605			-			155			605
Net proceeds from issuance of common stock under ESPP		428			661			198			359
Net cash provided by financing activities		1,033			661			353			964
Net decrease in cash, cash equivalents and restricted cash		(60,270	)		(67,836	)
Net increase (decrease) in cash, cash equivalents and restricted cash								24,667			(19,770	)
Cash, cash equivalents and restricted cash, beginning of period		88,729			173,513			21,261			88,729
Cash, cash equivalents and restricted cash, end of period	$	28,459		$	105,677		$	45,928		$	68,959
Supplemental disclosure of non-cash investing and financing activities
Conversion of Series F Convertible Preferred Stock into common stock	$	-		$	2,737
Cumulative-effect adjustment from adoption of ASU 2018-07	$	-		$	(160	)
Initial recognition of right-of-use lease asset	$	-		$	16,798
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	27,760		$	104,768		$	45,888		$	68,353
Restricted cash		699			909			40			606
Total cash, cash equivalents and restricted cash	$	28,459		$	105,677		$	45,928		$	68,959

La Jolla Pharmaceutical Company (collectively with its wholly owned subsidiaries, “La Jolla” or the “Company”) is dedicated to the ~~development and~~ commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA^TM™ (angiotensin II) ~~for~~ injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA^TM™ (eravacycline) for injection is ~~a novel fluorocycline of the tetracycline class of antibacterials that is~~ approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older.

On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. and its subsidiaries (“Tetraphase”), a biopharmaceutical company focused on commercializing XERAVA, for $43 million in upfront cash plus potential future cash payments of up to $16 million. The Company’s consolidated financial results ~~for periods ending September 30, 2020 and beyond include~~exclude Tetraphase’s financial results ~~subsequent~~prior to the acquisition closing date of July 28, 2020 (see Note ~~12)~~11).

In January 2021, La Jolla and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into a license agreement with PAION AG to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland. Pursuant to the agreement: (i) the Company has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax; and (ii) the Company is entitled to receive potential commercial milestone payments of up to $109.5 million and royalties on net sales of GIAPREZA and XERAVA.

As of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, the Company had cash and cash equivalents of ~~$27.8~~$45.9 million and ~~$87.8~~$21.2 million, respectively. Based on the Company’s current operating plans and projections, the Company expects that its existing cash and cash equivalents will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to fund future operations with existing cash or cash generated from operations.

The ~~accompanying~~Company’s condensed consolidated financial statements ~~of the Company~~ have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 108 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, ~~2019~~2020 included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2019,~~2020, filed with the SEC on March ~~2, 2020~~8, 2021 (the “Form 10-K”). The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.

The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net loss, shareholders’ ~~(deficit) equity~~deficit or cash flows. The results of operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 are not necessarily indicative of the results to be expected for the full year or any future interim periods. The accompanying condensed consolidated balance sheet as of December 31, ~~2019~~2020 has been derived from the audited consolidated balance sheet as of December 31, ~~2019~~2020 contained in the Form 10-K.

During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, other than the ~~short-term investments, business combinations, intangible assets and goodwill policies~~license revenue recognition policy described below, there have been no changes to the Company’s significant accounting policies as described in Note 2 of the Form 10-K.

Short-term investments are comprised of marketable equity securities that are “available-for-sale,” as such term is defined by the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 320. Marketable equity securities are classified as current assets. Short-term investments are measured at fair value, and unrealized gains and losses are recorded in other income (expense), net in the consolidated statements of operations. Overnight sweep accounts are classified as cash and cash equivalents.

Financial instruments that potentially subject the Company to concentration of credit risk consist of ~~cash and accounts receivable.~~cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits.

During the ~~nine~~six months ended ~~September~~June 30, ~~2020, 468~~2021, 399 hospitals in the U.S. purchased GIAPREZA. During the ~~nine~~six months ended ~~September~~June 30, ~~2020, 646~~2021, 644 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations purchase our products through a network of specialty and wholesale distributors. These specialty and wholesale distributors ~~(“Customers”).~~are considered our customers for accounting purposes. The Company does not believe that the loss of one of these distributors would significantly impact the ability to distribute ~~GIAPREZA or XERAVA,~~our products, as the Company expects that sales volume would be absorbed by the remaining distributors. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s 3 major ~~Customers,~~customers, each of which comprised 10% or more of its U.S. net product sales:

	U.S. Net Product Sales						Accounts Receivable
	Three Months Ended			Nine Months Ended						U.S. Net Product Sales						Accounts Receivable
	September 30, 2020			September 30, 2020			As of September 30, 2020			Three Months Ended June 30, 2021			Six Months Ended June 30, 2021			As of June 30, 2021
Customer A		37	%		38	%		28	%		34	%		36	%		37	%
Customer B		33	%		32	%		34	%		35	%		34	%		48	%
Customer C		26	%		27	%		33	%		27	%		26	%		12	%
Total		96	%		97	%		95	%		96	%		96	%		97	%

The Company has adopted FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”). Under ASC 606, the Company recognizes revenue when its Customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with Customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a Customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations. There have been no contract assets or liabilities recorded to date relating to product sales.

Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include:

~~The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly.~~

The Company accounts for business combinations using the acquisition method pursuant to ~~FASB ASC~~ the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 805. This method requires, among other things, that results of operations of acquired companies are included in La ~~Jolla's~~Jolla’s financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized as part of the Purchase Price at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities will be included in other (expense) income, ~~(expense),~~ net in the consolidated statements of operations. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized.

The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset.

The Company recognized 0 impairment charge for the six months ended June 30, 2021.

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized.

The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is ~~not the case, the Company has completed its goodwill impairment test and does not recognize an impairment charge. However, if that is~~ the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.

The Company recognized 0 impairment charge for the six months ended June 30, 2021.

Pursuant to FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations.

Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, Medicaid rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include:

The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly.

We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones.

If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition.

At the inception of each arrangement that include milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs.

For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery.

~~Management~~The Company has ~~considered~~implemented all ~~recent~~new accounting pronouncements that are in effect and ~~has concluded~~that may impact its financial statements and does not believe that there are ~~no recently issued~~any other new accounting pronouncements that ~~may~~have been issued that might have a material ~~effect~~impact on ~~the Company’s~~its financial position and results of ~~operations, financial condition or cash flows based on current information.~~operations.

Basic ~~net loss~~earnings (loss) per share is calculated by dividing net ~~loss~~income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted ~~net loss~~earnings (loss) per share is calculated by dividing net ~~loss~~income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock and stock options are considered potential common shares and are included in the calculation of diluted ~~net loss~~earnings (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted ~~net loss~~earnings (loss) per share when their effect is anti-dilutive. ~~As of September~~For the three months ended June 30, ~~2020 and 2019,~~2021, there were ~~10.0 million and 13.7~~6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 5,000 stock options. For the six months ended June 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 13,000 stock options. For the three and six months ended June 30, 2021 and 2020, there were 4.1 million and 10.2 million, respectively, of potential common shares that were excluded from the calculation of diluted ~~net~~ loss per share because their effect was anti-dilutive.

Restricted cash as of ~~September~~June 30, 2021 and December 31, 2020 ~~consists of: (i) a $0.5 million security deposit for the Company’s field force corporate credit card program; (ii) a $0.2 million standby letter~~consisted of ~~credit provided in lieu of a security deposit for the Watertown Lease (see Note 6); and (iii)~~ a $40,000 security deposit for the Company’s corporate purchasing credit card. ~~Restricted cash as of December 31, 2019 consists of a $0.9 million standby letter of credit provided in lieu of a security deposit for the San Diego Lease (see Note 6).~~

	September 30,		December 31,		June 30,		December 31,
	2020		2019		2021		2020
Raw materials	$	802	$	-	$	802	$	802
Work-in-process		2,340		1,505		3,636		3,213
Finished goods		4,132		706		1,043		1,998
Total inventory, net	$	7,274	$	2,211	$	5,481	$	6,013

As of ~~September~~June 30, 2021 and December 31, 2020, inventory, net ~~includes $2.1~~included 0 and $0.9 million, respectively, of the fair value step-up adjustment to Tetraphase’s inventory recorded in connection with the acquisition of Tetraphase (see Note ~~12)~~11). As of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, total inventory is recorded net of inventory reserves of ~~$0.2~~$1.2 million and ~~$0.1~~$0.9 million, respectively.

Prepaid expenses and other current assetsconsisted of the following (in thousands):

	September 30,			December 31,			June 30,			December 31,
	2020			2019			2021			2020
Furniture and fixtures							$	313		$	309
Computer hardware								310			310
Software	$	733		$	733			203			733
Furniture and fixtures		598			2,598
Leasehold improvements		386			14,504
Computer hardware		310			1,296
Lab equipment		-			9,665
Total property and equipment, gross		2,027			28,796			826			1,352
Accumulated depreciation and amortization		(1,743	)		(10,407	)		(663	)		(1,137	)
Total property and equipment, net	$	284		$	18,389		$	163		$	215

The Company recorded a loss of approximately $12.9 million, net of $3.1 million of cash proceeds, in other income (expense), net, related to the disposal of tenant improvements and certain equipment in connection with the termination of the San Diego Lease. The $12.9 million loss is recorded in the consolidated statements of cash flows net of the gain from the termination of the San Diego Lease (see Note 6).

	September 30,			December 31,		Useful Life	June 30,			December 31,
	2020			2019		(years)	2021			2020
Technology	$	14,000		$	-	10	$	14,000		$	14,000
Trade name		1,520			-	10		1,520			1,520
Total intangible assets, gross		15,520			-			15,520			15,520
Accumulated amortization		(259	)		-			(1,423	)		(647	)
Total intangible assets, net	$	15,261		$	-		$	14,097		$	14,873

The intangible assets were recorded in connection with the acquisition of Tetraphase (see Note ~~12)~~11).The Company recorded amortization expense of $0.4 million and $0.8 million for the three and six months ended June 30, 2021, respectively. The Company recorded 0 amortization expense for the six months ended June 30, 2020.

	September 30,		December 31,		June 30,		December 31,
	2020		2019		2021		2020
Accrued interest expense	$	3,870	$	2,692
Accrued interest expense on deferred royalty obligation, current portion					$	4,227	$	3,567
Deferred revenue						3,037		188
Accrued royalties and in-license fees						1,235		685
Accrued manufacturing costs		1,449		1,339		1,469		627
Accrued clinical study costs		426		3,496
Accrued professional fees						942		660
Accrued other		1,938		1,785		1,265		767
Total accrued expenses	$	7,683	$	9,312	$	12,175	$	6,494

	September 30,		December 31,		June 30,		December 31,
	2020		2019		2021		2020
Accrued interest expense	$	16,909	$	12,790
Fair value of CVRs (see Note 12)		2,610		-
Paycheck Protection Program loan		2,286		-	$	2,313	$	2,302
Fair value of contingent value rights (see Note 11)						2,180		1,810
Total other noncurrent liabilities	$	21,805	$	12,790	$	4,493	$	4,112

On April 22, 2020, Tetraphase entered into a promissory note for $2.3 million under the Paycheck Protection Program (the “PPP Loan”). The interest rate on the PPP Loan is 1.0% per annum. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration. The principal amount of the PPP Loan may be forgiven under the Paycheck Protection Program, subject to certain requirements and to the extent that the PPP Loan proceeds are used to pay permitted expenses, including certain payroll, rent and utility payments. The Company applied for forgiveness of the PPP Loan. The Company will be obligated to make monthly payments of principal and interest with respect to any unforgiven portion of the PPP Loan. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.

In May 2018, the Company closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, the Company received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10%. Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative net product sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by the Company’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA.

On receipt of the $125.0 million payment from HCR, the Company recorded a deferred royalty obligation of $125.0 million, net of issuance costs of $0.7 million. For the three and six months ended ~~September~~June 30, ~~2020~~2021, the Company recognized interest expense, including amortization of the obligation discount, of $2.7 million and ~~2019,~~$5.3 million, respectively. For the three and six months ended June 30, 2020, the Company recognized interest expense, including amortization of the obligation discount, of $2.5 million and ~~$2.8 million, respectively. For the nine months ended September 30, 2020 and 2019, the Company recognized interest expense, including amortization of the obligation discount, of$7.4 million and $8.4~~$4.9 million, respectively. The carrying value of the deferred royalty obligation as of ~~September~~June 30, 2021 and December 31, 2020 was $124.5 million and $124.4 million, respectively, net of unamortized obligation discount of $0.5 million and $0.6 million, respectively, and was classified as ~~noncurrent.~~a noncurrent liability. The related accrued interest expense ~~was $20.8 million and $15.5 million~~ as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020 was $26.4 million and $22.7 million, respectively, of which ~~$16.9~~$22.1 million and ~~$12.8~~$19.1 million was classified as ~~other~~ noncurrent liabilities, respectively. During the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, the Company made royalty payments to HCR of ~~$0.6~~$0.7 million and ~~$2.1~~$1.6 million, ~~respectively,~~respectively. As of June 30, 2021 and ~~as of September 30,~~December 31, 2020, the Company recorded royalty obligations payable of ~~$0.7~~$0.9 million and $0.9 million, respectively, in accrued expenses. The deferred royalty obligation is classified as Level 3 in the FASB ASC Topic 820-10, three-tier fair value hierarchy, and its carrying value approximates fair value.

Under the terms of the Royalty Agreement, La Jolla Pharma, LLC has certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA. If La Jolla Pharma, LLC is held to not have met these obligations, HCR would have the right to terminate the Royalty Agreement and demand payment from La Jolla Pharma, LLC of either $125.0 million or $225.0 million (depending on which obligation La Jolla Pharma, LLC is held to not have met), minus aggregate royalties already paid to HCR. In the event that La Jolla Pharma, LLC fails to timely pay such amount if and when due, HCR would have the right to foreclose on the GIAPREZA-related assets. The Company concluded that certain of these contract provisions that could result in an acceleration of amounts due under the Royalty Agreement are embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. The Company determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, the Company determined that the fair value of the embedded derivatives is immaterial as of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020. Each reporting period, the Company estimates the fair value of the embedded derivatives until the features lapse and/or the termination of the Royalty Agreement. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the consolidated statements of operations.

~~San Diego~~Future minimum lease payments, excluding Lease Operating Costs, as of June 30, 2021 are as follows (in thousands):

On December 29, 2016, the Company entered into an agreement with BMR-Axiom LP (the “Landlord”) to lease office and laboratory space as its corporate headquarters located at 4550 Towne Centre Court, San Diego, California (the “San Diego Lease”) for a period of 10 years commencing on October 30, 2017 (the “Initial Lease Term”). The Company had an option to extend the San Diego Lease for an additional 5 years at the end of the Initial Lease Term.

On August 6, 2020, La Jolla received notice from the Landlord that the Landlord exercised its option to terminate the San Diego Lease effective August 31, 2020. The Landlord exercised its right to terminate the San Diego Lease and recapture the property after La Jolla provided notice to the Landlord of its intent to assign the San Diego Lease. In connection with the termination of the San Diego Lease, La Jolla will have no further obligations under the San Diego Lease after the August 31, 2020 termination date, including with respect to future payments under the San Diego Lease. The Company recorded a non-cash gain of approximately $12.9 million as other income (expense), net, in connection with the write-off of the lease liability and corresponding right-of-use lease asset. The $12.9 million gain is recorded in the consolidated statements of cash flows net of the loss on disposal of property and equipment in connection with the termination of the San Diego Lease (see Note 4).

The Company provided a standby letter of credit for $0.9 million in lieu of a security deposit. This amount decreased to $0.6 million after year two of the Initial Lease Term. As of September 30, 2020, there was 0 cash pledged as collateral for such letter of credit and recorded as restricted cash.

~~As of September 30, 2020, there was 0 lease liability and corresponding right-of-use asset related to the San Diego Lease.~~ Lease expense ~~for the San Diego Lease~~under current leases was ~~$0.5~~approximately $0.1 million and ~~$1.8~~$0.2 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020, respectively, and~~2021, respectively. Lease expense under former leases was approximately $0.7 million and ~~$2.1~~$1.4 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively.

~~Watertown Lease~~ Cash paid for amounts included in the measurement of lease liabilities was $51,000 and $0.1 million for the three and six months ended June 30, 2021, respectively. Cash paid for amounts included in the measurement of lease liabilities was $1.0 and $1.9 million for the three and six months ended June 30, 2020, respectively. As of June 30, 2021, the weighted-average remaining lease term and the weighted-average discount rate for the Company’s only operating lease, the Waltham Sublease, was 2.3 years and 3.5%, respectively.

In December 2020, the Company entered into ana sublease agreement ~~with ARE-480 Arsenal Street, LLC, to lease~~for office ~~and laboratory~~ space ~~as its corporate headquarters located at 480 Arsenal Way, Watertown,~~in Waltham, Massachusetts (the ~~“Watertown Lease”~~“Waltham Sublease”). The ~~Watertown Lease originally provided for an expiration~~Waltham Sublease commenced on December 21, 2020 and expires on November 30, 2019. In November 2018, Tetraphase entered into an Eighth Amendment to the Watertown Lease to extend the term of the lease through November 30, 2022 (the “Lease Term”). In January 2020, Tetraphase entered into a Ninth Amendment to the Watertown Lease to surrender a portion of its leased space, which reduced the leased premises by a total of 15,899 square feet from approximately 37,438 square feet to approximately 21,539 square feet. Total aggregate remaining payments under the Watertown lease as of July 28, 2020 were $2.6 million.

Tetraphase provided a standby letter of credit for $0.2 million in lieu of a security deposit. As of September 30, 2020, $0.2 million of cash was pledged as collateral for such letter of credit and recorded as restricted cash. The annual rent under the Watertown Lease is subject to escalation during the Lease Term.2023. In addition to rent of approximately $15,000 per month, the ~~Watertown Lease~~Waltham Sublease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises (collectively, “Lease Operating Costs”). The ~~Watertown Lease~~Waltham Sublease contains customary default provisions, representations, warranties and covenants. The ~~Watertown Lease~~Waltham Sublease is classified as an operating lease. The Company recognizes the Waltham Sublease expense in the consolidated statements of operations and records a lease liability and right-of-use asset for this lease.

~~Future minimum lease payments, excluding Lease Operating Costs, under the Watertown Lease as of~~San Diego Sublease

~~As of July 28,~~ 2020, the Company ~~recorded~~entered into a sublease agreement for office space in San Diego, California with an entity of which the Chairman of the Company’s board of directors is also the chairman and chief executive officer (the “San Diego Sublease”). The San Diego Sublease term is approximately 7 years, and the rent is approximately $12,000 per month. The San Diego Sublease is cancellable without penalty by either party with 30-days’ written notice. The San Diego Sublease is a short-term lease for accounting purposes. The Company made payments of approximately $28,000 and $67,000 under the San Diego Sublease during the three and six months ended June 30, 2021. The Company recognizes the San Diego Sublease payments in the consolidated statements of operations and does not record a lease liability or right-of-use asset for the Watertown Lease based on the present value of the lease payments over the remaining Lease Term, discounted using the Company’s incremental borrowing rate. The Company recorded a corresponding right-of-use lease asset based on the lease liability. Subsequent to July 28, 2020 and through September 30, 2020, lease expense for the Watertown Lease was $0.2 million.this lease.

From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.

As of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, 3,906 shares of Series C-1² Convertible Preferred Stock (“Series C-1²Preferred”) were issued, outstanding and convertible into 6,735,378 shares of common stock. ~~In January 2019, the Company issued 782,031 shares of common stock upon the conversion of 2,737 shares of Series F Convertible Preferred Stock.~~ As of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019, there were 0 shares~~2020, the Series C-1² Preferred liquidation preference was approximately $3.9 million. The Series C-1² Preferred does not pay a dividend. The holders of the Series ~~F Convertible~~C-1² Preferred ~~Stock issued and outstanding.~~do not have voting rights, other than for general protective rights required by the California General Corporation Law.

A total of 9,600,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of ~~September~~June 30, 2021 and December 31, 2020, ~~6,061,242~~5,514,933 shares of common stock and 5,478,334 shares of common stock, respectively, remained available for future grants under the 2013 Equity Plan.

A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of ~~September~~June 30, 2021 and December 31, 2020, ~~480,368~~405,564 shares of common stock and 455,768 shares of common stock, respectively, remained available for future grants under the ESPP.

The activity related to equity awards, which are comprised of stock options, ~~and inducement grants,~~ during the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 is summarized as follows:

⁽¹⁾Represents the weighted-average remaining contractual term of stock options.

⁽²⁾ Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $4.28 as of June 30, 2021, and the exercise price.

The classification of share-based compensation expense is summarized as follows (in thousands):

	Three Months Ended				Nine Months Ended				Three Months Ended				Six Months Ended
	September 30,				September 30,				June 30,				June 30,
	2020		2019		2020		2019		2021		2020		2021		2020
Selling, general and administrative									$	977	$	626	$	1,817	$	1,470
Research and development	$	691	$	4,169	$	3,218	$	12,062		47		964		323		2,527
Selling, general and administrative		697		2,250		2,167		7,460
Total share-based compensation expense	$	1,388	$	6,419	$	5,385	$	19,522	$	1,024	$	1,590	$	2,140	$	3,997

As of ~~September~~June 30, ~~2020,~~2021, total unrecognized share-based compensation expense related to unvested equity awards was ~~$8.0~~$8.9 million, which is expected to be recognized over a weighted-average period of ~~2.6~~3.0 years. As of ~~September~~June 30, ~~2020,~~2021, there was no0 unrecognized share-based compensation expense related to shares of common stock issued under the ESPP.

The Company has a non-voting profits interest in a related party, which provides the Company with the potential to receive a portion of the future distributions of profits, if any. Investment funds affiliated with the Chairman of the Company’s board of directors have a controlling interest in the related party. During the ~~nine~~three and six months ended ~~September~~June 30, 2021, the Company received distributions of $2.5 million in connection with this profits interest. During the three and six months ended June 30, 2020, the Company received distributions of 0 and $4.1 million, respectively, in connection with this profits interest.

In December 2014, the Company entered into a patent license agreement with George Washington University (“GW”), which was subsequently amended and restated (the “GW License”) and assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, ~~the Company~~La Jolla Pharma, LLC is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA. The Company has paid a one-time license initiation fee, annual maintenance fees, an amendment fee, additional payments following the achievement of certain development and regulatory milestones and royalties. As a result of the European Commission’s approval of

GIAPREZA in August 2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020. The Company is obligated to pay a 6% royalty on net sales of ~~GIAPREZA.~~GIAPREZA and 15% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA. During the three and ~~nine~~six months ended ~~September~~June 30, 2021, the Company made payments to GW of $0.4 million and $3.2 million, respectively.During the three and six months ended June 30, 2020, the Company made ~~royalty~~ payments to GW of ~~$0.3~~$0.5 million and ~~$1.2~~$0.9 million, respectively.

In August 2006, ~~Tetraphase~~the Company entered into a license agreement with Harvard University (“Harvard”), which was subsequently amended and restated (the “Harvard License”). Pursuant to the Harvard License, Harvard exclusively licensed to the Company certain intellectual property rights relating to tetracycline-based products, including XERAVA, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA. For each product covered by the Harvard License, the Company is obligated to make certain payments ~~totaling~~for the following: (i) up to approximately ~~$15.1~~$15.1 million upon the achievement of certain clinical development and regulatory ~~milestones, and~~milestones; (ii) a 5% royalty on direct U.S. net sales of XERAVA; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA, starting at a minimum royalty rate of 4.5%, with step-ups to ~~pay Harvard tiered royalties at percentages in the single digits~~a maximum royalty of 7.5% based on the achievement of annual net product sales ~~if any, of tetracycline-based products, including XERAVA, by the Company, its affiliates~~thresholds; and ~~sublicensees in certain circumstances. The Company is also obligated to pay Harvard a specified share of non-royalty sublicensing and other revenues that it receives~~(iv) 20% on payments received from ~~sublicensees for the grant of sublicenses in certain circumstances, including the Everest License (see below), and to reimburse Harvard for specified patent prosecution and maintenance costs.~~sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA. ~~Subsequent to July 28, 2020~~During the three and ~~through September~~six months ended June 30, ~~2020,~~2021, the Company ~~paid $0.1 million of royalties~~made payments to Harvard of $1.5 million and ~~did 0t make any payments to Harvard~~$1.6 million, respectively, NaN of which related to clinical development and regulatory ~~milestone payments.~~milestones.

In March 2019, ~~Tetraphase~~the Company entered into a license agreement with Paratek Pharmaceuticals, Inc. (“Paratek”), which was subsequently amended and restated (the “Paratek License”). Pursuant to the Paratek License, Paratek non-exclusively licensed to the Company certain intellectual property rights relating to XERAVA, including non-exclusive rights to certain issued patents and patent applications covering XERAVA. ~~Under the Paratek License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell XERAVA.~~ The Company is obligated to pay Paratek ~~royalties at~~ a ~~low single digit percent~~2.25% royalty based on direct U.S. net sales of ~~XERAVA in the U.S.~~XERAVA. The Company’s obligation to pay royalties ~~under this agreement extends through~~with respect to the ~~last-to-expire patent covering XERAVA. Subsequent~~licensed product is retroactive to ~~July 28, 2020~~the date of the first commercial sale of XERAVA and ~~through September~~shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023. During the three and six months ended June 30, ~~2020,~~2021, the Company paid ~~$33,000~~$40,000 and $0.1 million, respectively, of royalties to Paratek.

On January 12, 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into an exclusive license agreement (the “PAION License”) with PAION AG and its wholly owned subsidiary (collectively, “PAION”). Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA and XERAVA in the PAION Territory. The Company has not received any payments from PAION related to either royalties or commercial milestones.

On July 13, 2021, the Company entered into a commercial supply agreement with PAION whereby the Company will supply PAION a minimum quantity of GIAPREZA and XERAVA through July 13, 2024.The supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial 3-year term of the supply agreement, the Company will be reimbursed for direct and certain indirect manufacturing costs at cost.

In February 2018, ~~Tetraphase~~the Company entered into a license agreement with Everest, ~~Medicines Limited (“Everest”),~~ which was subsequently amended and restated (the “Everest License”). Pursuant to the Everest License, ~~Tetraphase~~the Company granted Everest an exclusive license to develop and commercialize XERAVA for the treatment of cIAI and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the ~~“Territory”~~“Everest Territory”). The Company is eligible to receive ~~up to~~ an ~~aggregate of $11.0~~additional $8.0 million ~~in future clinical development and~~ regulatory milestone ~~payments~~payment and up to an aggregate of $20.0 million in sales milestone payments. The Company is also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. In ~~addition, royalties payable~~March 2021, the Company received a $3.0 million milestone payment associated with the submission of an NDA with the China National Medical Products Administration (“NMPA”) for XERAVA for the treatment of cIAI in patients in China. Amounts due under the ~~Everest~~Harvard License ~~will be subject to reduction~~for this milestone payment were included as research and development expense on ~~account~~the consolidated statements of ~~generic competition and after patent expiration in a jurisdiction, with any such reductions capped at certain percentages of~~operations.

In May 2021, the amounts otherwise payable during the applicable royalty payment period. Pursuant to the Everest License, Everest will be solely responsible for the development and commercialization of licensed products in the Territory. The Company agreed to use commercially reasonable efforts to manufacture drug product for clinical development, which will be paid by Everest at the cost to manufacture, as well as manufacture drug product for commercial supply, which will be paid by Everest at cost plus a reasonable margin. The Company has not yet entered into a commercial supply agreement with Everest ~~which would set~~whereby the Company will supply Everest a minimum quantity of XERAVA through December 31, 2023 and ~~timing of commercial supply. Subsequent~~will transfer to ~~July 28,~~

~~2020 and through September 30, 2020,~~Everest certain XERAVA-related manufacturing know-how. Pursuant to the supply agreement: (i) the Company has 0t received ~~any~~$6.8 million of upfront payments ~~from~~comprised of: (1) a $4.0 million upfront technology transfer payment; and (2) a $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest ~~related to either royalties or clinical development and regulatory milestones.~~

~~On December 2, 2019, the Board of Directors of~~during 2022; (ii) the Company ~~approved a restructuring plan (the “2019 Realignment”) that reduced~~will receive an additional $1.0 million technology transfer payment by January 30, 2022; and (iii) the ~~Company’s headcount. The 2019 Realignment did not result in any reductions in headcount in the Company’s commercial organization supporting its products. For the year ended~~Company will be reimbursed for direct and certain indirect manufacturing costs at 110% of costs through December 31, ~~2019, total expense was comprised of $5.8 million for one-time termination benefits to~~2023. The Company recognized the affected employees, including severance and health care benefits, offset by a $0.9 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of September 30, 2020, the Company had paid $4.9$5.0 million of the $5.8 million cash severance and health care benefits charges, and the remaining $0.2 million of the health care benefits charges were included in accrued payroll and related expenses. The Company expects to complete makingtechnology transfer-related payments ~~related to the 2019 Realignment by the end of the fourth quarter of 2020.~~

On May 28, 2020, the Board of Directors of the Company approved a restructuring plan (the “2020 Realignment”) to align its organization with the Company’s sole focus on the commercialization of its products. The 2020 Realignment reduced the Company’s headcount. For the nine months ended September 30, 2020, total expense was comprised of $4.1 million for one-time termination benefits to the affected employees, including severance and health care benefits, offset by a $0.4 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of September 30, 2020, the Company had paid $2.6 million of the $4.1 million cash severance and health care benefits charges, and the remaining $1.5 million of the cash severance and health care benefits charges were included in accrued payroll and related expenses. The Company expects to complete making substantially all of the payments related to the 2020 Realignment by the end of the first quarter of 2021.

~~In connection with the acquisition of Tetraphase, the Company incurred one-time charges related to a reduction in the combined Company’s headcount. For~~as license revenue during the three and ~~nine~~six months ended ~~September~~June 30, 2020, total expense was comprised of $3.1 million for one-time termination benefits to the affected employees, including severance and health care benefits. As of September 30, 2020, the Company had paid $1.3 million2021 as Everest obtained control of the $3.1 million cash severance and health care benefits charges, and the remaining $1.8 million of the cash severance and health care benefits charges were included in accrued payroll and related expenses.XERAVA-related manufacturing know-how prior to June 30, 2021. The Company ~~expects~~recognized the $2.8 million partial prepayment for XERAVA that is expected to ~~complete making substantially all~~be delivered to Everest during 2022 as deferred revenue as of June 30, 2021 as the ~~payments related~~performance obligation to ~~this headcount reduction by the end of the second quarter of 2021.~~deliver XERAVA has not yet been satisfied.

On June 24, 2020, La Jolla entered into an Agreement and Plan of Merger ~~(the “Merger Agreement”)~~ with Tetraphase, a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life‑threatening infections, and TTP Merger Sub, Inc., a wholly owned subsidiary of La Jolla. On July 28, 2020, La Jolla completed its acquisition of Tetraphase for $43 million in upfront cash plus potential future cash payments of up to $16 million pursuant to contingent value rights (“CVRs”). The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024. Following the acquisition, Tetraphase became a wholly owned subsidiary of La Jolla.

The acquisition of Tetraphase was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805. As the acquirer for accounting purposes, La Jolla has estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. The estimated fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value.

The Purchase Price is comprised of the upfront cash of $43 million and the estimated fair value of potential future cash payments pursuant to the CVRs. The estimated fair value of assets acquired was $54.7 million, and the estimated fair value of liabilities assumed was $9.1 million.

The Purchase Price allocation as of the acquisition date is presented as follows (in thousands):

	July 28,			July 28,
	2020			2020
Cash	$	42,990		$	42,990
Fair value of CVRs		2,610
Fair Value of CVRs					2,610
Total Purchase Price	$	45,600		$	45,600

Cash and cash equivalents		8,778		$	8,778
Accounts receivable		1,187			1,187
Inventory		4,767			4,767
Prepaid expenses and other current assets		1,218			1,218
Property and equipment		58			58
Right-of-use lease assets		2,302			2,302
Restricted cash		699			699
Identifiable intangible assets		15,520			15,520
Goodwill		20,123			20,123
Accounts payable		(1,400	)		(1,400	)
Accrued expenses		(2,979	)		(2,979	)
Lease liabilities, current portion		(967	)		(967	)
Lease liabilities, less current portion		(1,420	)		(1,420	)
Other noncurrent liabilities		(2,286	)		(2,286	)
Total Purchase Price	$	45,600		$	45,600

The estimated fair value of potential future cash payments pursuant to the CVRs was based on a Monte Carlo simulation and is classified as Level 3 in the ASC Topic 820-10, three-tier fair value hierarchy.

CVRs are measured at fair value on a recurring basis. During the three and six months ended June 30, 2021, the Company recorded a $0.1 million gain and $0.4 million loss, respectively, in other (expense) income in the consolidated statements of operations resulting from the change in fair value of CVRs.

The Company recorded a $3.3 million fair value step-up adjustment to Tetraphase’s inventory as of the acquisition date. Raw material components and active pharmaceutical ingredients were recorded based on estimated replacement cost. Finished drug product was valued at estimated selling cost, adjusted for costs of selling effort and a reasonable profit allowance for such selling effort from the viewpoint of a market participant. This fair value step-up adjustment is recorded as cost of ~~products~~product sales when the inventory is sold to ~~Customers, $1.2~~customers, 0 and $0.9 million of which was included in cost of product sales ~~subsequent to July 28, 2020~~ during the three and ~~through September~~six months ended June 30, ~~2020.~~2021, respectively.

Identifiable intangible assets consist of certain technology and trade names acquired from Tetraphase, and include the value of the Harvard, Paratek and Everest Licenses (see Note 10). The acquired intangible assets have definite useful lives and are being amortized on a straight-line basis over an estimated useful life of 10 years. ~~The acquired intangible assets are classified as Level 3 in the ASC Topic 820-10, three-tier fair value hierarchy.~~

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents the value of the stronger platform to increase patient access to the Company’s commercial products and the operational synergies of the combined Company. Goodwill has an indefinite useful life and is not amortized. The goodwill is only deductible for tax purposes if the Company makes a U.S. Internal Revenue Code Section 338 (“Section 338”) election. The Company ~~is currently evaluating whether to~~did not make a Section 338 election.

On May 28, 2020, ~~and through September 30, 2020, XERAVA U.S. net sales were $1.9 million and operating losses attributable to Tetraphase were $6.4 million, inclusive~~the Board of ~~$0.3 million of intangible asset amortization included in selling, general and administrative expense and $1.2 million~~Directors of the ~~inventory fair value step-up adjustment included~~Company approved a restructuring plan (the “2020 Realignment”) to align its organization with the Company’s sole focus on the commercialization of its products. The 2020 Realignment reduced the Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $4.1 million for one-time termination benefits to the affected employees, including severance and health care benefits, offset by a $0.4 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of June 30, 2021, the Company had made substantially all of the payments related to the 2020 Realignment.

In connection with the acquisition of Tetraphase, the Company incurred one-time charges related to a reduction in ~~cost~~the combined Company’s headcount. For the year ended December 31, 2020, total expense was comprised of ~~product sales.~~

~~Acquisition-related expenses, which were comprised primarily of legal fees, were $0.3 million and $0.9~~$3.1 million for one-time termination benefits to the affected employees, including severance and health care benefits. As of June 30, 2021, the Company had made substantially all of the payments related to this reduction in headcount.

For the three and ~~nine~~six months ended ~~September~~June 30, 2021, the Company recorded a provision for income taxes of 0 and $18,000, respectively. For the three and six months ended June 30, 2020, ~~respectively,~~the Company did 0t record a provision for income taxes. As of June 30, 2021 and December 31, 2020, the Company established a full valuation allowance against its federal and state deferred tax assets due to the uncertainty surrounding the realization of such assets. There were ~~included~~0 unrecognized tax benefits as of June 30, 2021 and December 31, 2020. The Company does not anticipate there will be a significant change in ~~selling, general and administrative expense.~~unrecognized tax benefits within the next 12 months.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and the related notes and other financial information included in our Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March ~~2, 2020~~8, 2021 (the “Form 10-K”).

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, and such statements may involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this Quarterly Report on Form 10-Q, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, future expenses, financing needs, plans or intentions relating to acquisitions, business trends and other information referred to under this section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “anticipate,” “target,” “forecast” or the negative of these terms and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Forward-looking statements are also based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. Such risks, uncertainties and other factors are described under “Risk Factors” in Item 1A of our Form 10-K for the year ended December 31, ~~2019 and under “Risk Factors” in Item 1A of this Quarterly Report on Form 10-Q.~~2020. We caution you that these risks, uncertainties and other factors may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will ~~result in the consequences or~~ affect us or our business in the way expected. All forward-looking statements in this Quarterly Report on Form 10-Q apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.

La Jolla Pharmaceutical Company is dedicated to the ~~development and~~ commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA^TM™ (angiotensin II) ~~for~~ injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA^TM™ (eravacycline) for injection ~~is a novel fluorocycline of the tetracycline class of antibacterials that~~ is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and ~~older.~~older.

On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. and its subsidiaries (“Tetraphase”), a biopharmaceutical company focused on commercializing XERAVA, for $43 million in upfront cash plus potential future cash payments of up to $16 million. ~~Financial~~La Jolla’s consolidated financial results ~~for periods ending September 30, 2020 and beyond include~~exclude Tetraphase’s financial results ~~subsequent~~prior to the acquisition closing date of July 28, 2020.

~~For~~In January 2021, La Jolla and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into a license agreement with PAION AG to commercialize GIAPREZA and XERAVA in the ~~three months ended September 30, 2020, GIAPREZA U.S.~~European Economic Area, the United Kingdom and Switzerland. Pursuant to the agreement: (i) the Company has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax; and (ii) the Company is entitled to receive potential commercial milestone payments of up to $109.5 million and royalties on net sales ~~were $7.2 million, up 24% from the three months ended June 30, 2020~~of GIAPREZA and ~~up 26% from the three months ended September 30, 2019. For the nine months ended September 30, 2020, GIAPREZA U.S. net sales were $20.6 million, up 30% from the same period in 2019.~~

Subsequent to July 28, 2020 and through September 30, 2020, XERAVA U.S. net sales were $1.9 million. For the three months ended September 30, 2020, XERAVA U.S. net sales were $2.7 million, up 80% from the three months ended June 30, 2020 and up 170% from the three months ended September 30, 2019. For the nine months ended September 30, 2020, XERAVA U.S. net sales were $5.9 million, up 181% from the same period in 2019.XERAVA.

European Union: GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies

GIAPREZA^TM™ (angiotensin II) ~~for~~ injection is approved by the FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (“EC”) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system (“RAAS”), which in turn regulates blood pressure. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned ~~subsidiary.~~subsidiary, and is marketed in Europe by PAION Deutschland GmbH on behalf of La Jolla Pharma, LLC.

XERAVA^TM™ (eravacycline) for injection ~~is a novel fluorocycline of the tetracycline class of antibacterials that~~ is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of ~~cIAI~~complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older. XERAVA is approved by the EC for the treatment of cIAI in adults. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La ~~Jolla.~~Jolla, and is marketed in Europe by PAION Deutschland GmbH on behalf of Tetraphase. Everest, the Company’s licensee for mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines, recently submitted an NDA in China, which was accepted by the China National Medical Products Administration (“NMPA”) in March 2021.

In connection with the acquisition of Tetraphase, we acquired the following product candidates that are in ~~early-stage~~early stage clinical ~~or preclinical~~ development: (1) TP-6076, an IV formulation of a ~~fully-synthetic~~fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; (2) TP-271, an IV and oral formulation of a ~~fully-synthetic~~fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and (3) TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. At this time, there are no active studies nor anticipated future studies for any of these product candidates. We intend to seek ~~out-licensing~~out-license opportunities for these product ~~candidates,~~candidates; however, at this time, we are unable to predict the likelihood of successfully out-licensing any of these product ~~candidates.~~candidates.

The following table summarizes our results of operations for each of the periods below (in thousands):

	Three Months Ended									Nine Months Ended									Three Months Ended									Six Months Ended
	September 30,									September 30,									June 30,									June 30,
	2020			2019			Change			2020			2019			Change			2021			2020			Change			2021			2020			Change
Net product sales	$	9,072		$	5,706		$	3,366		$	22,468		$	15,804		$	6,664		$	11,059		$	5,805		$	5,254		$	19,696		$	13,396		$	6,300
License revenue																				5,000			-			5,000			30,500			-			30,500
Cost of product sales		2,489			554			1,935			4,013			1,605			2,408			2,156			808			1,348			4,887			1,524			3,363
Cost of license revenue																				-			-			-			3,600			-			3,600
Selling, general and administrative expense																				8,996			8,677			319			17,751			16,829			922
Research and development expense		3,617			21,182			(17,565	)		21,581			64,469			(42,888	)		1,114			8,781			(7,667	)		2,672			17,964			(15,292	)
Selling, general and administrative expense		12,493			10,782			1,711			29,322			34,425			(5,103	)
Other income (expense), net		(2,233	)		(2,362	)		129			(3,495	)		(6,580	)		3,085
Net loss	$	(11,760	)	$	(29,174	)	$	17,414		$	(35,943	)	$	(91,275	)	$	55,332
Other (expense) income, net																				(60	)		(3,131	)		3,071			(3,117	)		(1,262	)		(1,855	)
Provision for income taxes																				-			-			-			18			-			18
Net income (loss)																			$	3,733		$	(15,592	)	$	19,325		$	18,151		$	(24,183	)	$	42,334

~~Financial results for periods ending September 30, 2020 and beyond include Tetraphase’s~~La Jolla’s consolidated financial results ~~subsequent to the acquisition closing date of July 28, 2020. Net loss~~ for the three and ~~nine~~six months ended ~~September~~June 30, 2020 ~~includes purchase price accounting adjustments~~exclude the financial results of $1.5 million. Net loss for the three and nine months ended September 30, 2020 also includes $0.3 million and $0.9 million of one-time acquisition-related expenses. We expect our research and development expense and selling, general and administrative expense to decrease in the near term as we realize the benefits from integrating the operations ofTetraphase. La Jolla ~~and Tetraphase.~~

Net product sales consist ~~solely~~ of revenue recognized from sales of GIAPREZA and XERAVA to hospitals and other healthcare organizations in the U.S. through a network of specialty and ~~wholesaler~~wholesale distributors ~~(“Customers”)~~. ~~GIAPREZA U.S.~~These specialty and wholesale distributors are considered our customers for accounting purposes.

La Jolla’s net product sales were ~~$7.2~~$11.1 million and ~~$20.6~~$19.7 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, compared to ~~$5.7~~$5.8 million and ~~$15.8~~$13.4 million, respectively, for the same periods in ~~2019. Subsequent to~~2020. La Jolla acquired Tetraphase, which commercialized XERAVA, on July 28, 2020. Net product sales excludes XERAVA for the three and six months ended June 30, 2020.

GIAPREZA U.S. net sales were $8.6 million and $15.4 million for the three and six months ended June 30, 2021, respectively, compared to $5.8 million and $13.4 million for the same periods in 2020. GIAPREZA U.S. net sales increased during the three and six months ended June 30, 2021 compared to the same periods in 2020 ~~and through September 30, 2020,~~due to an increase in the number of vials sold to our customers. XERAVA U.S. net sales were ~~$1.9 million. XERAVA U.S. net sales were $2.7~~$2.5 million and ~~$5.9~~$4.3 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020, respectively,~~2021, compared to ~~$1.0 million and $2.1 million, respectively,~~zero for the same periods in ~~2019.~~2020.

License revenue consists of revenue from out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development, regulatory or commercial milestone payments; and/or (iii) sales-based royalties. License revenue also consists of revenue from commercial supply agreements with our out-licensees to supply a minimum quantity of our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases.

License revenue was $5.0 million for the three months ended June 30, 2021, which consists of the transfer of certain XERAVA-related manufacturing know-how to Everest in connection with the Everest commercial supply agreement. License revenue was $30.5 million for the six months ended June 30, 2021, which consists of: (i) a $22.5 million upfront cash payment in connection with the PAION License; (ii) a $3.0 million regulatory milestone cash payment in connection with the Everest License; and (iii) $5.0 million for the transfer of certain XERAVA-related manufacturing know-how to Everest in connection with the Everest commercial supply agreement. The Company did not record license revenue during the three and six months ended June 30, 2020.

Cost of product sales consists primarily of expense associated with: (i) royalties payable to George Washington University, Harvard University and Paratek Pharmaceuticals, Inc.; (ii) manufacturing; (iii) the inventory fair value step-up adjustment recorded in connection with the acquisition of Tetraphase; ~~(iii) manufacturing;~~and (iv) ~~regulatory fees; and (v)~~ shipping and distribution.

Cost of product sales ~~was $2.5~~were $2.2 million and ~~$4.0~~$4.9 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, compared to ~~$0.6~~$0.8 million and ~~$1.6~~$1.5 million, respectively, for the same periods in ~~2019. Subsequent to July 28, 2020~~2020. Cost of product sales excludes XERAVA for the three and ~~through September~~six months ended June 30, ~~2020,~~2020. For the three and six months ended June 30, 2021, cost of product sales includes ~~$1.2~~zero and $0.9 million, respectively, of the inventory fair value step-up adjustment recorded in connection with the acquisition of Tetraphase.

Cost of license revenue consists of amounts due under in-license agreements in connection with license revenuefrom commercially approved product. Cost of license revenue recognized in connection with product that is not commercially approved is recorded as research and development expense. Cost of license revenue was zero and $3.6 million for the three and six months ended June 30, 2021, respectively, which consists of amounts due under the George Washington University and Harvard University license agreements in connection with the upfront cash payment received from the PAION License. The Company did not record cost of license revenue during the three and six months ended June 30, 2020.

Selling, general and administrative expense consists of non-personnel and personnel expenses. Non-personnel-related expense includes expense related to: (i) professional fees for legal, patent, consulting, accounting and audit services; (ii) sales and marketing costs such as speaker programs, advertising and promotion; and (iii) facilities and information technology. Personnel-related expense includes expense related to salaries, benefits and share-based compensation for personnel engaged in sales, finance and administrative functions. We do not expect our selling, general and administrative expense to change significantly in the near term.

The following table summarizes these expenses for each of the periods below (in thousands):

	Three Months Ended							Six Months Ended
	June 30,							June 30,
	2021		2020		Change			2021		2020		Change
Non-personnel expense:
Sales and marketing	$	1,315	$	588	$	727		$	2,510	$	1,811	$	699
Professional fees		1,266		1,356		(90	)		2,794		2,227		567
Facility		105		554		(449	)		119		1,047		(928	)
Other		811		339		472			1,603		925		678
Total non-personnel expense		3,497		2,837		660			7,026		6,010		1,016
Personnel expense:
Salaries, bonuses and benefits		4,522		3,261		1,261			8,908		7,396		1,512
One-time charges for reductions in headcount		-		1,953		(1,953	)		-		1,953		(1,953	)
Share-based compensation expense		977		626		351			1,817		1,470		347
Total personnel expense		5,499		5,840		(341	)		10,725		10,819		(94	)
Total selling, general and administrative expense	$	8,996	$	8,677	$	319		$	17,751	$	16,829	$	922

During the three and six months ended June 30, 2021, total selling, general and administrative non-personnel expense increased compared to the same period in 2020 primarily resulting from the inclusion of Tetraphase-related costs, which are excluded from La Jolla’s financial results for the three and six months ended June 30, 2020.

During the three and six months ended June 30, 2021, total selling, general and administrative personnel expense decreased compared to the same periods in 2020 primarily as a result of one-time charges in 2020 resulting from a reduction of headcount from a Company-wide realignment in May 2020; partially offset by an increase in headcount resulting from the acquisition of Tetraphase.

Research and development expense consists of non-personnel and personnel expenses. Non-personnel-related expense includes expense related to: (i) amounts due under in-license agreements for drug product that is not commercially approved; (ii) manufacturing development; (iii) facilities and information technology; and (iv) conducting clinical studies. Personnel-related expense includes expense related to salaries, benefits and share-based compensation for personnel engaged in research and development functions. We expect our research and development expense to decrease in the near term.

The following table summarizes these expenses for each of the periods below (in thousands):

	Three Months Ended							Nine Months Ended							Three Months Ended							Six Months Ended
	September 30,							September 30,							June 30,							June 30,
	2020		2019		Change			2020		2019		Change			2021		2020		Change			2021		2020		Change
Non-personnel expense:
GIAPREZA	$	832	$	1,641	$	(809	)	$	3,675	$	4,662	$	(987	)	$	304	$	1,762	$	(1,458	)	$	479	$	2,843	$	(2,364	)
XERAVA		511		-		511			511		-		511			154		-		154			416		-		416
LJPC-401																72		-		72			102		1,531		(1,429	)
LJPC-0118		9		424		(415	)		926		1,559		(633	)		11		404		(393	)		16		917		(901	)
LJPC-401		-		4,552		(4,552	)		1,531		13,347		(11,816	)
Other programs		28		1,204		(1,176	)		28		5,047		(5,019	)
Facility		312		1,879		(1,567	)		2,872		5,455		(2,583	)		2		1,124		(1,122	)		5		2,560		(2,555	)
Other		198		1,089		(891	)		672		3,007		(2,335	)		153		149		4			726		673		53
Total non-personnel expense	$	1,890	$	10,789	$	(8,899	)	$	10,215	$	33,077	$	(22,862	)		696		3,439		(2,743	)		1,744		8,524		(6,780	)
Personnel expense:
Salaries, bonuses and benefits		1,036		6,224		(5,188	)		8,148		19,330		(11,182	)		371		1,933		(1,562	)		605		4,468		(3,863	)
One-time charges for reductions in headcount																-		2,445		(2,445	)		-		2,445		(2,445	)
Share-based compensation expense		691		4,169		(3,478	)		3,218		12,062		(8,844	)		47		964		(917	)		323		2,527		(2,204	)
Total personnel expense	$	1,727	$	10,393	$	(8,666	)	$	11,366	$	31,392	$	(20,026	)		418		5,342		(4,924	)		928		9,440		(8,512	)
Total research and development expense	$	3,617	$	21,182	$	(17,565	)	$	21,581	$	64,469	$	(42,888	)	$	1,114	$	8,781	$	(7,667	)	$	2,672	$	17,964	$	(15,292	)

During the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, total research and development non-personnel expense decreased compared to the same periods in 2020 primarily as a result ofof: (i) decreases in program-related expenses as we de-prioritized our product candidates and focused on the commercialization of GIAPREZA and ~~XERAVA. Further,~~XERAVA; (ii) decreases in manufacturing development-related expenses for GIAPREZA; and (iii) decreases in facility-related expenses ~~decreased~~ primarily as a result of the termination of our lease for office and laboratory space in San Diego, ~~Lease~~California effective August 31, ~~2020 (see Note 6~~2020; partially offset by increases in manufacturing and clinical development costs related to the ~~condensed consolidated financial statements included in Item 1~~acquisition of ~~this Quarterly Report on Form 10-Q).~~XERAVA.

During the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, total research and development personnel expense, including share-based compensation expense, decreased compared to the same periods in 2020 as a result ofof: (i) reduced ~~headcount in 2020 from a Company-wide realignment in November 2019, partially offset by: (i) $2.4 million of~~ headcount; (ii) one-time charges in 2020 resulting from a reduction of headcount from a Company-wide realignment in May ~~2020;~~2020; and ~~(ii) $0.8 million of one-time charges~~(iii) a decrease in ~~2020 resulting from a reduction of headcount from combining La Jolla and Tetraphase~~ personnel ~~in July 2020.~~

~~Selling, general and administrative expense consists of non-personnel and personnel expenses. The following table summarizes these expenses for each of the periods below (in thousands):~~

Three Months Ended

Nine Months Ended

September 30,

September 30,

2020

2019

Change

2020

2019

Change

Non-personnel expense:

Professional fees

$
1,946

$
981

$
965

$
4,173

$
3,076

$
1,097

Facility

941

394

547

1,988

1,167

821

Sales and marketing

782

1,509

(727
)

2,593

5,001

(2,408
)
Other

1,045

669

376

1,970

1,856

114

Total non-personnel expense

$
4,714

$
3,553

$
1,161

$
10,724

$
11,100

$
(376
)
Personnel expense:

Salaries, bonuses and benefits

7,082

4,979

2,103

16,431

15,865

566

Share-based compensation expense

697

2,250

(1,553
)

2,167

7,460

(5,293
)
Total personnel expense

$
7,779

$
7,229

$
550

$
18,598

$
23,325

$
(4,727
)
Total selling, general and administrative expense

$
12,493

$
10,782

$
1,711

$
29,322

$
34,425

$
(5,103
)

~~During the three months ended September 30, 2020~~, total selling, general and administrative non-personnel expense increased primarily as a result of increases in professional fee-related expenses, partially offset by decreases in sales and marketing-related expenses. During the nine months ended September 30, 2020, total selling, general and administrative non-personnel expense decreased primarily as a result of decreases in sales and marketing-related expenses, partially offset by increases in professional fee-related expenses. During the three and nine months ended September 30, 2020, La Jolla incurred one-time acquisition-related expenses of $0.3 million and $0.9 million, respectively. During the three and nine months ended September 30, 2020, facility-related expenses allocated to selling, general and administrative increased as a result of increased selling, general and administrative headcount relativeallocations to research and development ~~headcount.~~activities in 2021.

~~During~~Tetraphase’s research and development expense is excluded from La Jolla’s financial results for the three and six months ended ~~September~~June 30, 2020, total selling, general and administrative personnel expense, including share-based compensation expense, increased as a result of $2.3 million of one-time charges resulting from a reduction of headcount from combining La Jolla and Tetraphase personnel in July 2020, partially offset by reduced headcount in 2020 from Company-wide realignments in November 2019 and May 2020. During the nine months ended September 30, 2020, total selling, general and administrative personnel expense, including share-based compensation expense, decreased as a result of reduced headcount in 2020 from a Company-wide realignment in November 2019, partially offset by: (i) $1.7 million of one-time charges in 2020 resulting from a reduction of headcount from a Company-wide realignment in May 2020;~~and (ii) $2.3 million of one-time charges in 2020 resulting from a reduction of headcount from combining La Jolla and Tetraphase personnel in July~~ 2020.

Other (expense) income, ~~(expense),~~ net consists of the ~~receipt of~~following: (i) interest expense accrued for our deferred royalty obligation; (ii) income from distributions received in connection with our non-voting profits interest in a related ~~party, interest accrued for our deferred royalty obligation, gains~~party; (iii) gain (loss) from changes in the fair value of contingent value rights (“CVRs”); and ~~losses associated with the disposal of certain property and equipment, and~~(iv) interest income generated from cash held in savings ~~accounts.~~accounts.

During the three months ended ~~September~~June 30, ~~2020,~~2021, other ~~expense,~~(expense) income, net ~~remained consistent~~was $(0.1) million, compared to ~~the same period in 2019. During the nine months ended September 30, 2020, other expense, net decreased to $3.5 million from $6.6~~$(3.1) million for the same period in ~~2019, a decrease of $3.1 million.~~2020. This ~~decrease~~$3.0 million increase in other (expense) income, net was primarily due toto: (i) a $2.5 million increase in the receipt of distributions ~~of $4.1 million~~ in connection with the Company’s non-voting profits interest in a related ~~party~~party; and (ii) a ~~$1.0~~$0.9 million decrease in loss on disposal of equipment; partially offset by a $0.2 million increase in interest expense for our deferred royalty ~~obligation, partially offset by~~obligation.

During the six months ended June 30, 2021, other (expense) income, net was $(3.1) million, compared to $(1.3) million for the same period in 2020. This $1.8 million decrease in other (expense) income, net was primarily due to: (i) a $1.6 million decrease in the receipt of distributions in connection with the Company’s non-voting profits interest in a related party; (ii) a $0.4 million decrease in loss from changes in the fair value of CVRs; (iii) a $0.4 million increase in interest expense for our deferred royalty obligation; and (iv) a $0.2 million decrease in interest income generated from cash held in savings ~~accounts.~~accounts; partially offset by a $0.9 million decrease in loss on disposal of equipment.

As of ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, we had cash and cash equivalents of ~~$27.8~~$45.9 million and ~~$87.8~~$21.2 million, respectively. ~~On July 28, 2020, La Jolla completed the acquisition of Tetraphase for $43.0 million in upfront cash.~~ Based on our current operating plans and projections, we believe that our existing cash and cash equivalents will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC. The Company expects to fund future operations with existing cash or cash generated from operations.

~~Net~~La Jolla’s net cash ~~used for~~provided by (used for) operating activities for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 was ~~$9.8~~$7.1 million and ~~$30.4~~$24.3 million, respectively, ~~down 48% and 55%, respectively, from the same periods in 2019. Net cash used for operating activities for the three and nine months ended September 30, 2020, excluding cash expenditures related~~compared to ~~reductions in headcount and transaction costs associated with the Tetraphase acquisition, was $5.6~~$(8.4) million and $21.6 million, respectively, down 70% and 67%, respectively, from the same periods in 2019. Cash expenditures related to reductions in headcount were $3.3 million and $7.9 million for the three and nine months ended September 30, 2020, respectively, and zero and $2.3$(20.6) million, respectively, for the same periods in ~~2019. Cash expenditures~~2020. Net cash provided by (used for) operating activities for the three and six months ended June 30, 2021, excluding net receipts in connection with out-license agreements, commercial supply agreements and payments related to ~~transaction costs associated~~reductions in headcount, was $2.2 million and $0.4 million, respectively, compared to $(6.7) million and $(16.0) million, respectively, for the same periods in 2020. Net receipts (payments) in connection with ~~the Tetraphase acquisition~~out-license agreements were ~~$0.9~~$(1.4) million and $18.4 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020.~~

~~Cash used~~2021,respectively, and zero for ~~investing activities was $30.9 million and $0.7~~the same periods in 2020. Net receipts in connection with commercial supply agreements were $6.8 million for the ~~nine~~three and six months ended ~~September~~June 30, ~~2020~~2021, and ~~2019, respectively. The increase~~zero for the same periods in cash used for investing activities resulted primarily from the acquisition of Tetraphase, net of cash, cash equivalents and restricted cash acquired, partially offset by proceeds from the sale of property and equipment.

~~Cash provided by financing activities was $1.0~~2020. Payments related to reductions in headcount were $0.5 million and ~~$0.7~~$1.3 million for the ~~nine~~three and six months ended ~~September~~June 30, ~~2020~~2021, respectively, and ~~2019, respectively. The increase in cash provided by financing activities was primarily the result of net proceeds from issuance of common stock under employee stock plans.~~

Since January 2012, when the Company was effectively restarted, through September 30, 2020, our cash used in operating activities was $456.3 million. As of September 30, 2020, we had an accumulated deficit of $1,073.3$1.6 million and ~~have financed~~$4.6 million, respectively, for the same periods in 2020.

The amount and timing of additional future funding needs, if any, will depend on many factors, including the success of our ~~operations~~commercialization efforts for GIAPREZA and XERAVA and our ability to control expenses. If necessary, we will raise additional capital through ~~public and private offerings of securities, a royalty~~equity or debt financings. We can provide no assurance that additional financing ~~revenues from net product sales, interest income~~will be available to us on ~~invested cash balances and other income.~~favorable terms, or at all.

In December 2014, the Company entered into a patent license agreement with George Washington University (“GW”), which was subsequently ~~was~~ amended and restated (the “GW License”) and assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, ~~the Company~~La Jolla Pharma, LLC is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA. The Company has paid a one-time license initiation fee, annual maintenance fees, an amendment fee, additional payments following the achievement of certain development and regulatory milestones and royalties. As a result of the European Commission’s approval of GIAPREZA in August

2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020. The Company is obligated to pay a 6% royalty on net sales of ~~GIAPREZA.~~GIAPREZA and 15% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering ~~GIAPREZA.~~GIAPREZA.

In August 2006, ~~Tetraphase~~the Company entered into a license agreement with Harvard University (“Harvard”), which was subsequently amended and restated (the “Harvard License”). Pursuant to the Harvard License, Harvard exclusively licensed to the Company certain intellectual property rights relating to tetracycline-based products, including XERAVA, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA. For each product covered by the Harvard License, the Company is obligated to make certain payments ~~totaling~~for the following: (i) up to approximately $15.1 million upon the achievement of certain clinical development and regulatory ~~milestones, and~~milestones; (ii) a 5% royalty on direct U.S. net sales of XERAVA; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA, starting at a minimum royalty rate of 4.5%, with step-ups to ~~pay Harvard tiered royalties at percentages in the single digits~~a maximum royalty of 7.5% based on the achievement of annual net product sales ~~if any, of tetracycline-based products, including XERAVA, by the Company, its affiliates~~thresholds; and ~~sublicensees in certain circumstances. The Company is also obligated to pay Harvard a specified share of non-royalty sublicensing and other revenues that it receives~~(iv) 20% on payments received from ~~sublicensees for the grant of sublicenses in certain circumstances, including the Everest License (see below), and to reimburse Harvard for specified patent prosecution and maintenance costs.~~sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including ~~XERAVA.~~XERAVA.

~~Paratek License, the~~The Company is obligated to pay Paratek a 2.25% royalty based on direct U.S. net sales of XERAVA. The Company’s obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023.

On January 12, 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, entered into an exclusive license agreement with PAION AG and its wholly owned subsidiary (collectively, “PAION”) (the “PAION License”). Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to ~~develop,~~ commercialize ~~market~~GIAPREZA and ~~sell XERAVA. The Company is obligated pay Paratek royalties at a low single digit percent based on net sales of~~ XERAVA in the ~~U.S.~~PAION Territory. The ~~obligation~~Company has not received any payments from PAION related to ~~pay~~either royalties ~~under this~~or commercial milestones.

On July 13, 2021, the Company entered into a commercial supply agreement ~~extends~~with PAION whereby the Company will supply PAION a minimum quantity of GIAPREZA and XERAVA through July 13, 2024. The supply agreement will automatically renew until the ~~last-to-expire patent covering XERAVA.~~

~~Out-license Agreement~~earlier of July 13, 2027, or until a new supply agreement is executed. During the initial 3-year term of the supply agreement, the Company will be reimbursed for direct and certain indirect manufacturing costs at cost.

containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. In ~~addition, royalties payable under~~March 2021, the ~~Everest License will be subject to reduction on account~~Company received a $3.0 million milestone payment associated with the submission of ~~generic competition and after patent expiration in a jurisdiction,~~an NDA with ~~any such reductions capped at certain percentages of~~ the ~~amounts otherwise payable during the applicable royalty payment period. Pursuant to the Everest License, Everest will be solely responsible~~China NMPA for XERAVA for the ~~development and commercialization~~treatment of ~~licensed products~~cIAI in patients in China.

In May 2021, the ~~Territory. The~~ Company agreed to use commercially reasonable efforts to manufacture drug product for clinical development, which will be paid by Everest at the cost to manufacture, as well as manufacture drug product for commercial supply, which will be paid by Everest at cost plus a reasonable margin. The Company has not yet entered into a commercial supply agreement with Everest ~~which would set~~whereby the Company will supply Everest a minimum quantity of XERAVA through December 31, 2023 and ~~timing of commercial supply. Subsequent~~will transfer to ~~July 28, 2020 and through September 30, 2020,~~Everest certain XERAVA-related manufacturing know-how. Pursuant to the supply agreement: (i) the Company has received $6.8 million of upfront payments comprised of: (1) a $4.0 million upfront technology transfer payment; and (2) a $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022; (ii) the Company will receive an additional $1.0 million technology transfer payment by January 30, 2022; and (iii) the Company will be reimbursed for direct and certain indirect manufacturing costs at 110% of costs through December 31, 2023. The Company recognized the $5.0 million of technology transfer-related payments as license revenue during the three and six months ended June 30, 2021 as Everest obtained control of the XERAVA-related manufacturing know-how prior to June 30, 2021. The Company recognized the $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022 as deferred revenue as of June 30, 2021 as the performance obligation to deliver XERAVA has not ~~received any payments from Everest related to either royalties or clinical development and regulatory milestones.~~yet been satisfied.

We have no ~~off-balance~~off−balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in our financial condition, expenses, results of operations, liquidity, capital expenditures or capital ~~resources.~~resources.

We believe the estimates, assumptions and judgments involved in the accounting policies described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 of our Form 10-K for the year ended December 31, ~~2019~~2020 are most critical to understanding and evaluating our reported financial results. During the ~~three and nine~~six months ended ~~September~~June 30, ~~2020,~~2021, other than the ~~business combinations accounting~~license revenue recognition policy described ~~below,~~in Note 2 to our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q, there have been no material changes to the critical accounting policies and estimates as described in Item 7 of our Form 10-K for the year ended December 31, ~~2019.~~

The Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in La Jolla's financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized as part of the Purchase Price at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities will be included in other income (expense), net in the consolidated statements of operations. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition

~~date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.~~2020.

See Note 2 to our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

Item 3. Quantitative and Qualitative ~~Disclosure~~Disclosures about Market Risk

We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.

Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of ~~September~~June 30, ~~2020,~~2021, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

There was no change in our internal control over financial reporting that occurred during our most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

From time to time, we may become subject to claims and litigation arising in the ordinary course of business. We are not a party to any material legal proceedings, nor are we aware of any material pending or threatened litigation.

~~An investment~~Our business is subject to various risks, including those described in ~~shares~~Item 1A of our ~~common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below and the other information contained in this Quarterly~~Annual Report on Form ~~10-Q before deciding to invest~~10-K for the year ended December 31, 2020. There have been no material changes from the risk factors disclosed in ~~shares~~Item 1A of our common stock. The risks described below are not the only ones facing our Company. Additional risks not presently known to us or that we currently consider immaterial may also adversely affect our business. We have attempted to identify below the major factors that could cause differences between actual and planned or expected results, but we cannot assure you that we have identified all of those factors. Our business, financial condition, results of operations and prospects could be materially adversely affected by any of these risks or uncertainties. In such case, the trading price of shares of our common stock could decline, and you could lose all or part of your investment.

~~We are substantially dependent on the commercial success of GIAPREZA~~^TM ~~(angiotensin II) and~~ ~~XERAVA~~^TM ~~(eravacycline)~~.

~~The success of our business is substantially dependent on our ability to successfully commercialize GIAPREZA~~^TM ~~(angiotensin II) and XERAVA~~^TM (eravacycline), our commercial products. The market for effective pharmaceutical sales and marketing professionals is competitive, and maintaining these capabilities is expensive and challenging. If we are unable to maintain an effective sales and marketing organization, GIAPREZA and XERAVA sales could be adversely affected, and our business could suffer.

In the U.S. and most major foreign markets, drugs like GIAPREZA and XERAVA that are administered in the hospital must be purchased by the hospital and generally are not directly reimbursed by third-party payors. Hospitals instead are reimbursed for patient cases based on patients’ diagnosed conditions under the U.S. Medicare diagnosis-related group (“DRG”) system or other like systems for non-Medicare patients in the U.S. and in most major foreign markets. Adoption of new drugs that are administered in the hospital generally occurs more slowly than adoption of new drugs that are taken on an outpatient basis, which generally are paid for by third-party payors. If we are unsuccessful at convincing hospitals and health care providers to increase their rate of adoption of GIAPREZA and XERAVA, our business will suffer.

~~Catecholamines (primarily norepinephrine), which are available as generics and inexpensive, are typically used in the first line to treat distributive shock, while Vasostrict~~^® (Endo International plc) is typically used in the second line. In the randomized, Phase 3 study ATHOS-3, GIAPREZA demonstrated clinical benefit in patients who were not adequately responding to available vasopressors, including catecholamines and Vasostrict. GIAPREZA’s principle competition as a treatment in patients not adequately responding to available vasopressors is the use of these same vasopressors, particularly norepinephrine, at increased doses. If we are unable to successfully change treatment practices, the commercial prospects for GIAPREZA will be limited, and our business will suffer.

~~XERAVA competes with a number of antibiotics that are currently marketed for the treatment of~~ ~~cIAI~~ ~~and other multidrug resistant infections, including: AVYCAZ (ceftazidime and avibactam, marketed by AbbVie Inc.); MERREM IV~~^® ~~(meropenem, marketed by AstraZeneca PLC); PRIMAXIN~~^® ~~(imipenem and cilastatin, marketed by Merck & Co., Inc.); RECARBRIO™ (imipenem, cilastatin, and relebactam, marketed by Merck & Co., Inc.); TYGACIL~~^® ~~(tigecycline, marketed by Pfizer Inc.); VABOMERE™ (meropenem and vaborbactam, marketed by Melinta Therapeutics, Inc.); ZERBAXA~~^® ~~(ceftolozane and tazobactam, marketed by Merck & Co., Inc.); ZOSYN~~^® (piperacillin and tazobactam, marketed by Pfizer Inc.); and current and future generic versions of marketed antibiotics. If we are unable to successfully change treatment practices, the commercial prospects for XERAVA will be limited, and our business will suffer.

Our estimates of the potential market sizes for GIAPREZA and XERAVA are based on prescription and sales data for relevant in-market products, the results of clinical studies, medical literature and other information. If

~~the potential market sizes for GIAPREZA and XERAVA are smaller than our estimates, the commercial prospects for GIAPREZA and XERAVA may be limited, and our business may suffer.~~

~~The commercial success of GIAPREZA and XERAVA will depend on our ability to obtain an uninterrupted supply of GIAPREZA and XERAVA from our contract manufacturers.~~

We do not currently own or operate manufacturing facilities for the production of GIAPREZA or XERAVA. We rely on sole-source third-party manufacturers to produce GIAPREZA and XERAVA and expect to continue to do so to meet our development and commercial needs. In all of our manufacturing agreements, we require that third-party contract manufacturers produce active pharmaceutical ingredients (“APIs”) and drug products in accordance with the U.S. Food and Drug Administration’s (“FDA’s”) current Good Manufacturing Practices (“cGMPs”) and all other applicable laws and regulations. The long-term commercial success of GIAPREZA and XERAVA will depend in part on the ability of our contract manufacturers to supply cGMP-compliant API and drug product without interruption. If there is an interruption in the supply of GIAPREZA and XERAVA from our contract manufacturers, our business will suffer.

Our ability to realize the benefits from the acquisition of Tetraphase is substantially dependent on the commercial success of XERAVA and the cost savings resulting from the timely and effective integration of the operations of La Jolla and Tetraphase.

Our ability to realize the benefits from the acquisition of Tetraphase is substantially dependent on our ability to successfully commercialize XERAVA. Combining with La Jolla may not accelerate XERAVA’s availability to patients in need, and our presence in the hospital may not increase with a second innovative therapy. If we are unsuccessful at convincing hospitals and health care providers to increase their rate of adoption of XERAVA, our sales could be adversely affected, and our business could suffer.

Further, our ability to realize the benefits from the acquisition of Tetraphase is substantially dependent on the cost savings resulting from the timely and effective integration of the operations of La Jolla and Tetraphase. The process of integrating the operations of La Jolla and Tetraphase could encounter unexpected costs and delays, which include: the loss of key personnel; the loss of key customers; the loss of key suppliers; and unanticipated issues in integrating sales, marketing and administrative functions. If we are unable to timely and effectively integrate the operations of La Jolla and Tetraphase, our costs could be adversely affected, and our business could suffer. Further, even if the integration is timely and effective, we may never realize the cost savings expected from the integration of the operations of our two companies.

~~GIAPREZA’s and XERAVA’s market exclusivity periods will depend on the validity and enforceability of issued and pending patents covering GIAPREZA and XERAVA.~~

As of September 30, 2020, we owned or had in-licensed 12 issued U.S. patents, 9 pending U.S. patent applications, 5 issued foreign patents and 45 pending foreign patent applications that cover GIAPREZA. The U.S. patents and patent applications expire between 2029 and 2040, and the foreign patents and patent applications expire between 2034 and 2040.

As of September 30, 2020, we owned or had in-licensed 3 issued U.S. patents, 1 pending U.S. patent applications, 16 issued foreign patents and 6 pending foreign patent applications that cover XERAVA. The U.S. patents and patent applications expire between 2023 and 2030, and the foreign patents and patent applications expire between 2029 and 2040.

As of September 30, 2020, we have also filed applications for Supplementary Protection Certificates based on European Patent No. 2323972 covering the composition of matter and use of XERAVA. Some applications have been granted and others are pending.

As of September 30, 2020, we also owned 1 pending U.S. patent application and 9 pending foreign patent applications that cover crystalline forms of eravacycline. Any U.S. patents that may be issued will expire in 2037 absent any adjustment, extension or filing of a terminal disclaimer. Likewise, any foreign patents that may be issued will expire in 2037.

Although we believe the bases for these patents and patent applications are sound, they are untested, and there is no assurance that they will not be successfully challenged. There can be no assurance that any patent previously issued will protect GIAPREZA or XERAVA from generic competition or that any patent application will

result in an issued patent that will protect GIAPREZA or XERAVA from generic competition. Furthermore, there can be no assurance that GIAPREZA or XERAVA will not be held to infringe valid patents held by others. If our owned and in-licensed intellectual property do not protect GIAPREZA or XERAVA from generic competition, GIAPREZA or XERAVA sales will decline, and our business will suffer. If either GIAPREZA or XERAVA is held to infringe valid patents held by others, we could be subject to liability, and our business could suffer.

~~Product liability lawsuits against us could cause us to incur substantial liabilities and reduce GIAPREZA and XERAVA sales.~~

Patients suffering from distributive shock are gravely ill and have a high mortality rate. Although 28-day mortality in patients treated with GIAPREZA was lower than in patients treated with placebo in the randomized, Phase 3 study ATHOS-3, there was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients treated with GIAPREZA in this study. Some patients who are treated with GIAPREZA will die due to their underlying illness or suffer adverse events (which may or may not be drug related). Additionally, patients suffering from cIAI may become gravely ill and may die due to underlying illness or suffer adverse events (which may or may not be drug related). As such, we may face product liability lawsuits. Although we carry product liability insurance, product liability lawsuits against us could cause us to incur substantial liabilities and reduce GIAPREZA and XERAVA sales. Furthermore, any such lawsuits could impair our business reputation and result in the initiation of investigations by regulators.

~~Our ability to continue commercializing GIAPREZA and XERAVA is dependent on our fulfillment of contractual obligations to certain parties.~~

In May 2018, we closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, we received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of 10%. Starting January 1, 2022, the maximum royalty rate may increase by 4% if an agreed-upon, cumulative net product sales threshold has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by our wholly-owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA. However, under the terms of the Royalty Agreement, La Jolla Pharma, LLC has certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA. If La Jolla Pharma, LLC is held to not have met these obligations, HCR would have the right to terminate the Royalty Agreement and demand payment from La Jolla Pharma, LLC of either $125.0 million or $225.0 million (depending on which obligation La Jolla Pharma, LLC is held to not have met), minus aggregate royalties already paid to HCR. In the event that La Jolla Pharma, LLC fails to timely pay such amount if and when due, HCR would have the right to foreclose on the GIAPREZA-related assets.

In December 2014, we entered into a patent license agreement with George Washington University (“GW”), which was subsequently amended and restated (the “GW License”) and assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to us certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, La Jolla Pharma, LLC is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA and make certain payments to GW, including a 6% royalty on net sales of GIAPREZA. If La Jolla Pharma, LLC is held to not have met its obligations, GW could terminate the GW License and La Jolla Pharma, LLC would no longer have rights to the GW issued patents and patent applications covering GIAPREZA.

In August 2006, Tetraphase entered into a license agreement with Harvard University (“Harvard”), which was subsequently amended and restated (the “Harvard License”). Pursuant to the Harvard License, Harvard

exclusively licensed to the Company certain intellectual property rights relating to tetracycline-based products, including XERAVA, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA. For each product covered by the Harvard License, the Company is obligated to make certain payments totaling up to approximately $15.1 million upon the achievement of certain clinical development and regulatory milestones, and to pay Harvard tiered royalties at percentages in the single digits based on net sales, if any, of tetracycline-based products, including XERAVA, by the Company, its affiliates and sublicensees in certain circumstances. The Company is also obligated to pay Harvard a specified share of non-royalty sublicensing and other revenues that it receives from sublicensees for the grant of sublicenses in certain circumstances, including the Everest License (see below), and to reimburse Harvard for specified patent prosecution and maintenance costs. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA. If Tetraphase is held to not have met its obligations, Harvard could terminate the Harvard License and Tetraphase would no longer have rights to the Harvard issued patents and patent applications covering XERAVA.

In March 2019, Tetraphase entered into a license agreement with Paratek Pharmaceuticals, Inc. (“Paratek”), which was subsequently amended and restated (the “Paratek License”). Pursuant to the Paratek License, Paratek non-exclusively licensed to the Company certain intellectual property rights relating to XERAVA, including non-exclusive rights to certain issued patents and patent applications covering XERAVA. Under the Paratek License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell XERAVA. The Company is obligated pay Paratek royalties at a low single digit percent based on net sales of XERAVA in the U.S. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering XERAVA. If Tetraphase is held to not have met its obligations, Paratek could terminate the Paratek License and Tetraphase would no longer have rights to the Paratek issued patents and patent applications covering XERAVA.

In February 2018, Tetraphase entered into a license agreement with Everest Medicines Limited (“Everest”), which was subsequently amended and restated (the “Everest License”). Pursuant to the Everest License, Tetraphase granted Everest an exclusive license to develop and commercialize XERAVA for the treatment of cIAI and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the “Territory”). The Company is eligible to receive up to an aggregate of $11.0 million in future clinical development and regulatory milestone payments and up to an aggregate of $20.0 million in sales milestone payments. The Company is also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Territory until the latest to occur of: (1) the last-to-expire of specified patent rights in such jurisdiction in the Territory; (2) expiration of marketing or regulatory exclusivity in such jurisdiction in the Territory; or (3) 10 years after the first commercial sale of a product in such jurisdiction in the Territory. In addition, royalties payable under the Everest License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction, with any such reductions capped at certain percentages of the amounts otherwise payable during the applicable royalty payment period. Pursuant to the Everest License, Everest will be solely responsible for the development and commercialization of licensed products in the Territory. The Company agreed to use commercially reasonable efforts to manufacture drug product for clinical development, which will be paid by Everest at the cost to manufacture, as well as manufacture drug product for commercial supply, which will be paid by Everest at cost plus a reasonable margin. The Company has not yet entered into a commercial supply agreement with Everest, which would set the quantity and timing of commercial supply. Subsequent to July 28, 2020 and through September 30, 2020, the Company has not received any payments from Everest related to either royalties or clinical development and regulatory milestones. ~~If Tetraphase is held to not have met its obligations, the commercial prospects for XERAVA in the Territory will be limited, and our business will suffer.~~

As of October 30, 2020, we employed 65 employees. The market for effective professionals in the pharmaceutical industry is competitive, and hiring and retaining these professionals is expensive and challenging. If we are unable to hire and retain key employees, we may be unable to effectively execute on our operating plan, and our business could suffer.

~~Business interruptions resulting from geopolitical actions, natural disasters, public health crises or other catastrophic events could have an adverse impact on our business.~~

Business interruptions resulting from geopolitical actions, such as war and terrorism, natural disasters, public health crises, such as a pandemic, or other catastrophic events could have an adverse impact on our business. For example, if one of these events were to adversely affect one of our contract manufacturers, our supply of GIAPREZA and XERAVA could be interrupted. Furthermore, in the case of a pandemic, the ability of our critical care specialists to access hospitals and call on physicians may be curtailed, which may adversely affect product sales.

~~Our overall financial performance, including but not limited to net product sales and net cash used for operating activities, may not meet our expectations.~~

Our overall financial performance, including but not limited to net product sales and net cash used for operating activities, is difficult to predict and may fluctuate from quarter to quarter and year to year. Historical financial performance may not be indicative of future financial performance. For example, our net product sales may be below expectations, and our costs to operate our business, including cost of product sales, research and development expenses and selling, general and administrative expenses, could exceed our estimates. If our overall financial performance does not meet our expectations, our business could suffer.

~~Our capital requirements and our potential need for, and ability to obtain, additional financing are uncertain.~~

As of September 30, 2020, we had cash of $27.8 million. GIAPREZA and XERAVA are our approved products and our only sources of product revenue. The amount and timing of future funding requirements, if any, will depend on many factors, including the success of our commercialization efforts for GIAPREZA and XERAVA, and our ability to control expenses. If necessary, we will raise additional capital through equity or debt financings or collaboration agreements. We can provide no assurance that additional financing will be available to us on favorable terms, or at all. If we need to raise additional capital and are unable to do so, we may be forced to curtail or cease our operations.

~~The ongoing COVID-19 pandemic may disrupt our operations and affect our ability to sell GIAPREZA and XERAVA.~~

We are unable to accurately predict the full impact that the ongoing Coronavirus Disease 2019 (“COVID‑19”) pandemic will have on our results from operations, financial condition and our ability to sell GIAPREZA and XERAVA due to numerous factors that are not within our control, including its duration and severity of the outbreak. Stay-at-home orders, business closures, travel restrictions, supply chain disruptions and employee illness or quarantines could result in disruptions to our operations, which could adversely impact our results from operations and financial condition. In addition, the COVID-19 pandemic has resulted in ongoing volatility in financial markets. If our access to capital is restricted or associated borrowing costs increase as a result of developments in financial markets relating to the COVID-19 pandemic, our operations and financial condition could be adversely impacted.

~~We are subject to various federal, state and foreign laws and regulations governing the health care industry that could result in substantial penalties for noncompliance.~~

We are subject to various federal, state and foreign laws and regulations governing the health care industry that could result in substantial penalties for noncompliance. These laws and regulations may impact our ability to operate, including our sales and marketing efforts. In addition, we may be subject to patient privacy regulation by federal, state and foreign governments that govern jurisdictions in which we conduct our business. The laws and regulations that may affect our ability to operate include:

If we are found to be in violation of any of the laws or regulations described above or any other laws or regulations that apply to us, we may be subject to substantial penalties, including civil and criminal penalties, damages, fines and possible exclusion from participation in Medicare, Medicaid and other federal health care programs. If we are subjected to substantial penalties, our business will suffer, and we may be forced to curtail or cease our operations

~~Drug development involves a lengthy and expensive process with an uncertain outcome.~~

Drug development involves a lengthy and expensive process with an uncertain outcome. Failure can occur at any time during drug development. The results of nonclinical studies and early clinical studies may not be predictive of the results of later-stage clinical studies. For example, the safety or efficacy results of clinical studies do not ensure that later clinical studies will demonstrate similar results. Even if clinical studies demonstrate the safety and efficacy of the product candidate, there is no assurance that such product candidate will receive regulatory approval.

~~Drugs approved by the FDA, European Commission (“EC”) and/or other regulatory agencies are subject to ongoing regulation.~~

Any products manufactured or distributed by us pursuant to FDA, EC and/or other regulatory agency approvals may be subject to continuing regulation by such agencies, including record-keeping requirements and reporting of adverse experiences with the drug. Drug manufacturers and their subcontractors are required to

register their establishments with the FDA, EC and/or other regulatory agencies and may be subject to periodic unannounced inspections by such agencies for compliance with cGMPs, which impose certain procedural and documentation requirements on us and our third-party manufacturers. Even after regulatory approval is obtained, under certain circumstances, such as later discovery of previously unknown safety risks, the FDA, EC and/or other regulatory agencies can withdraw approval or subject the drug to additional restrictions.

~~The price per share of our common stock may fluctuate significantly, and you may lose all or part of your investment.~~

The price per share of our common stock may fluctuate significantly, and you may lose all or part of your investment. These fluctuations could be based on various factors, including factors described elsewhere in this QuarterlyAnnual Report on Form ~~10-Q and below:~~10-K.

~~We have never paid a dividend on shares of our common stock, and you should rely on price appreciation of shares of our common stock for return on your investment.~~

We have never paid a dividend on shares of our common stock. Even if we decide to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations, financial condition, contractual restrictions and other factors. You should not rely on dividend income from shares of our common stock and should rely on price appreciation of shares of our common stock for return on your investment.

~~Conversion of our convertible preferred stock would result in substantial dilution for our existing shareholders of common stock.~~

As of September 30, 2020, there were approximately 27.4 million shares of common stock outstanding. We may be required to issue up to approximately 6.7 million additional shares of common stock upon conversion of existing convertible preferred stock. The issuance of these additional shares would represent approximately 20% dilution to our existing shareholders of common stock.

If we need to obtain additional financing in the future, such financing could result in dilution to your investment, adversely affect the price per share of our common stock and/or create future operating and financial restrictions.

As of September 30, 2020, we had cash of $27.8 million. GIAPREZA and XERAVA are our approved products and our only source of product revenue. The amount and timing of future funding requirements, if any, will depend on many factors, including the success of our commercialization efforts for GIAPREZA and XERAVA and our ability to control expenses. If necessary, we will raise additional capital through equity or debt financings. We can provide no assurance that additional financing will be available to us on favorable terms, or at all. If we issue additional equity securities or securities convertible into equity securities, you will suffer dilution to your investment, and such issuance may adversely affect the price per share of our common stock. Any new debt financing we enter into may involve covenants that restrict our operations, which may include limitations on borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens or pay dividends.

In connection with the acquisition of Tetraphase, the Company incurred one-time charges related to a reduction in the combined Company’s headcount. For the three and nine months ended September 30, 2020, total expense was comprised of $3.1 million for one-time termination benefits to the affected employees, including severance and health care benefits. As of September 30, 2020, the Company had paid $1.3 million of the $3.1 million cash severance and health care benefits charges, and the remaining $1.8 million of the cash severance and health care benefits charges were included in accrued payroll and related expenses. The Company expects to complete making substantially all of the payments related to this headcount reduction by the end of the second quarter of 2021.None.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

California		33-0361285
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

~~4747 Executive Drive,~~201 Jones Road, Suite ~~240, San Diego, CA~~400, Waltham, MA		~~92121~~02451
(Address of principal executive offices)		(Zip Code)

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements	1

Condensed Consolidated Balance Sheets as of ~~September~~June 30, ~~2020~~2021 (Unaudited) and December 31, ~~2019~~2020	1

Condensed Consolidated Statements of Operations for the Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 (Unaudited)	2

Condensed Consolidated Statements of Shareholders’ ~~(Deficit) Equity~~Deficit for the Three and ~~Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 (Unaudited)	3

Condensed Consolidated Statements of Cash Flows for the ~~Three and Nine~~Six Months Ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 (Unaudited)	54

Notes to Condensed Consolidated Financial Statements (Unaudited)	65

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	1718

Item 3. Quantitative and Qualitative Disclosures about Market Risk	2426

Item 4. Controls and Procedures	2426

PART II. OTHER INFORMATION	2527

Item 1. Legal Proceedings	2527

Item 1A. Risk Factors	2527

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	3127

Item 3. Defaults upon Senior Securities	3227

Item 4. Mine Safety Disclosures	3227

Item 5. Other Information	3227

Item 6. Exhibits	3227

SIGNATURES	3328

	June 30,		December 31,
	2021		2020
Refundable withholding tax	$	3,375	$	-
Prepaid manufacturing costs		491		930
Prepaid clinical costs		265		820
Prepaid insurance		263		505
Other prepaid expenses and current assets		807		1,133
Total prepaid expenses and other current assets	$	5,201	$	3,388

2020	$	281
2021		1,138
2022		1,027
Thereafter		-
Total future minimum lease payments		2,446
Less: discount		(212	)
Total lease liabilities	$	2,234

2021	$	108
2022		181
2023		166
Thereafter		-
Total future minimum lease payments		455
Less: discount		36
Total lease liabilities	$	419

	Equity Awards			Weighted- average Exercise Price per Share		Weighted- average Remaining Contractual Term⁽¹⁾ (years)		Aggregate Intrinsic Value⁽²⁾ (millions)
Outstanding at December 31, 2020		4,121,666		$	8.67
Granted		562,329		$	4.96
Exercised		(29,379	)	$	5.23
Cancelled/forfeited		(569,549	)	$	9.21
Outstanding at June 30, 2021		4,085,067		$	8.10		8.3	$	0.2
Exercisable at June 30, 2021		1,107,878		$	16.71		5.7	$	-

	Equity Awards			Weighted-average Exercise Price per Share		Weighted-average Remaining Contractual Term (years)		Aggregate Intrinsic Value
Outstanding at December 31, 2019		5,616,840		$	19.50
Granted		1,802,860		$	4.70
Exercised		(94,219	)	$	6.42
Cancelled/forfeited		(4,000,059	)	$	18.74
Outstanding at September 30, 2020		3,325,422		$	12.77		7.43	$	-
Exercisable at September 30, 2020		1,466,036		$	20.53		5.52	$	-

Exhibit No.		Exhibit Description

~~10.1~~+3.1		~~Employment Offer Letter by~~Amended and ~~between~~Restated Articles of Incorporation of La Jolla Pharmaceutical Company (incorporated herein by reference to Exhibit 4.1 to the Company’s Form S-8, as filed with the SEC on December 20, 2013)

3.2		La Jolla Pharmaceutical Company Amended and ~~Larry Edwards dated~~Restated Bylaws (incorporated herein by reference to Exhibit 3.4 to the Company’s Form S-8-A12B/A, as ~~of July 28, 2020~~filed with the SEC on October 17, 2014)

31.1		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

+		~~Indicates a management contract or compensatory plan or arrangement~~

			La Jolla Pharmaceutical Company

Date:	~~November 9, 2020~~August 5, 2021	By:	/s/ Larry Edwards
			Larry Edwards
			Director, President and Chief Executive Officer
			(principal executive officer)

			/s/ Michael Hearne
			Michael Hearne
			Chief Financial Officer
			(principal financial and accounting officer)

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company